<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Nov. 22, 2019 (HealthDay News) — Testosterone replacement is associated with an improvement in body composition among younger male cancer survivors with low-normal morning total serum testosterone, according to a study published online Nov. 12 in PLOS Medicine<\/i>.<\/p>\n
Jennifer S. Walsh, M.B.Ch.B., Ph.D., from the University of Sheffield in the United Kingdom, and colleagues randomly assigned (1:1) 136 male survivors of testicular cancer, lymphoma, and leukemia (aged 25 to 50 years) to receive either testosterone (Tostran 2 percent gel) or placebo for 26 weeks. Participants all had morning total serum testosterone of 7 to 12 nmol\/L and were matched for body mass index.<\/p>\n
The researchers found that at the end of the trial, testosterone treatment was associated with decreased trunk fat mass (\u22120.9 kg; 95 percent confidence interval, \u22121.6 to \u22120.3; P = 0.0073), decreased whole-body fat mass (\u22121.8 kg; 95 percent confidence interval, \u22122.9 to \u22120.7; P = 0.0016), and increased lean body mass (1.5 kg; 95 percent confidence interval 0.9 to 2.1; P < 0.001) compared with placebo. The greatest decrease in fat mass was seen in patients with a high truncal fat mass at baseline. No association was seen between treatment effect and physical function or any other quality of life scores.<\/p>\n
“The results of this study have significant benefits alongside improvements in body composition, potentially offsetting the risk of increased mortality from heart disease,” a coauthor said in a statement.<\/p>\n
Several authors disclosed financial ties to pharmaceutical and diagnostic companies.<\/p>\n